2428-2429 / 2953
EORTC-22961: Superior survival with
long-term adjuvant HT
•
PCa mortality for short- and
long-term adjuvant HT was
4.7% and 3.2%, respectively
–
Significant difference in PCa
survival (HR=1.71; p=0.002)
Locally advanced prostate cancer
T1c to T2a–b (N1/N2, M0) or
T2c to T4 (N0–N2, M0)
(n=970)
EBRT + GnRH agonist +
•
5-year overall mortality was
19.0% and 15.2% short- and
long-term groups,
respectively
–
HR=1.42 (p=0.65 for non-
inferiority)
antiandrogen for 6 months
GnRH agonist
for 30
months
(n=487)
Follow-up
(n=483)
Randomized
Bolla M, et al. NEJM 2009;360:2516–27
EBRT, external-beam radiotherapy; HT, hormone therapy
BM13